Denali Therapeutics Inc (DNLI) — Cash Flow-to-Debt Ratio
Denali Therapeutics Inc (DNLI) has a Cash Flow-to-Debt Ratio of -0.39x as of March 2026, meaning its operating cash flow of $-131.20 Million could theoretically repay 0% of its total liabilities ($339.93 Million) in one year. Explore Denali Therapeutics Inc (DNLI) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Denali Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Denali Therapeutics Inc across 11 annual periods. Also explore Denali Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Denali Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Denali Therapeutics Inc. For market capitalisation and broader financial context, see DNLI market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | $-412.60 Million | $131.09 Million | ▼ -30.8% |
| 2024 | -2.41x | $-347.69 Million | $144.50 Million | ▲ +17.3% |
| 2023 | -2.91x | $-357.99 Million | $122.96 Million | ▼ -397.1% |
| 2022 | -0.59x | $-244.72 Million | $417.81 Million | ▼ -22.4% |
| 2021 | -0.48x | $-211.39 Million | $441.87 Million | ▼ -152.2% |
| 2020 | 0.92x | $416.15 Million | $453.75 Million | ▲ +195.8% |
| 2019 | -0.96x | $-151.58 Million | $158.34 Million | ▼ -319.9% |
| 2018 | 0.44x | $50.12 Million | $115.14 Million | ▲ +111.9% |
| 2017 | -3.66x | $-76.64 Million | $20.93 Million | ▲ +16.2% |
| 2016 | -4.37x | $-72.36 Million | $16.55 Million | ▼ -1419.8% |
| 2015 | -0.29x | $-15.05 Million | $52.32 Million | — |